secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcadia Biosciences, Inc. (RKDA)
CIK:        0001469443
Form:       8-K
Filed at:   2021-09-07T23:59:59+00:00
Accession:  0000950170-21-001688
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcadia Biosciences launches CEO search; Matt Plavan to step down when successor named
--------------------------------------------------------------------------------

- National CEO search underway as Arcadia expands CPG portfolio; successor expected by year-end 2021.
- CEO Matt Plavan will step down once successor is named; he has led since 2019, transitioning Arcadia from ag-biotech to CPG.
- Transition Agreement: if terminated without cause before Dec 1 2021, Plavan receives $30,833/month consulting through Nov 30 2021.
- Severance: $61,666 on Jan 1 2022, $61,666 on Feb 1 2022, $143,278 on Mar 1 2022; full option vesting conditioned on release.
- Chairman Kevin Comcowich thanked Plavan for leading through a critical transformation and pandemic.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1469443/000095017021001688/0000950170-21-001688-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1469443/000095017021001688/rkda-20210903.htm
  HTML page:      https://secwatch.observer/filing/0000950170-21-001688

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer